Search hospitals > Ohio > Columbus
Nationwide Children's Hospital
Claim this profileColumbus, Ohio 43205
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Brain Tumor
Conducts research for Cystic Fibrosis
Conducts research for Lymphoblastic Leukemia-Lymphoma
1069 reported clinical trials
67 medical researchers
Summary
Nationwide Children's Hospital is a medical facility located in Columbus, Ohio. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Cystic Fibrosis, Lymphoblastic Leukemia-Lymphoma and other specialties. Nationwide Children's Hospital is involved with conducting 1,069 clinical trials across 1,138 conditions. There are 67 research doctors associated with this hospital, such as Mark Ranalli, Pablo Sanchez, MD, Maryam Fouladi, MD, and Bhuvana Setty, M.D..Area of expertise
1Leukemia
Global LeaderPhiladelphia chromosome positive
BCR-ABL1 positive
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Mark RanalliNationwide Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
69 reported clinical trials
120 drugs studied
Pablo Sanchez, MDResearch Institute at Nationwide Children's Hospital6 years of reported clinical research
Studies Premature Birth
Studies Premature Infants
12 reported clinical trials
18 drugs studied
Maryam Fouladi, MDNationwide Children's Hospital1 year of reported clinical research
Expert in Brain Tumor
Studies Diffuse Intrinsic Pontine Glioma
13 reported clinical trials
20 drugs studied
Bhuvana Setty, M.D.Nationwide Children's Hospital3 years of reported clinical research
Studies Sarcoma
Studies Ewing Sarcoma
10 reported clinical trials
20 drugs studied
Clinical Trials running at Nationwide Children's Hospital
Acute Myeloid Leukemia
Brain Tumor
Acute Lymphoblastic Leukemia
Acute Leukemia
Astrocytoma
Rhabdomyosarcoma
Leukemia
Germ Cell Tumors
Cancer
Hypophosphatemic Rickets
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Nationwide Children's Hospital?
Nationwide Children's Hospital is a medical facility located in Columbus, Ohio. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Cystic Fibrosis, Lymphoblastic Leukemia-Lymphoma and other specialties. Nationwide Children's Hospital is involved with conducting 1,069 clinical trials across 1,138 conditions. There are 67 research doctors associated with this hospital, such as Mark Ranalli, Pablo Sanchez, MD, Maryam Fouladi, MD, and Bhuvana Setty, M.D..
Where is Nationwide Children's Hospital located?
To reach Nationwide Children's Hospital, located at 700 Children's Drive, Columbus, OH 43205, take I-70 or I-670 to the 700 Children's Drive exit. Follow the blue path marked by colored flooring stripes and three-part directions to navigate within the hospital. For real-time driving directions, consider using Waze.
Who should I call to ask about financial aid or insurance network?
**Nationwide Children's Hospital Financial and Insurance Assistance**
- **Financial Assistance:** For aid, call (614) 466-1700 or visit the Children with Medical Handicaps (CMH) website. Programs include Nationwide Children's Hospital Financial Assistance, Hospital Care Assurance Program (HCAP), Ohio Healthy Start, Healthy Families, MiChild, Healthy Kids – Michigan Department of Health and Human Services, Children with Medical Handicaps (CMH), Ohio Medicaid for the Disabled and Aged, and Health Care Exchanges.
- **Insurance Matters:** For insurance inquiries, dial (888) 908-2498 or check their website for billing and insurance info, including financial assistance and health insurance details.
- **Billing or Insurance Questions:** Contact Patient Account Representatives at (614) 722-2055 or email Children'sPatientAccounts@NationwideChildrens.org for assistance with billing issues or insurance queries.
- **General Inquiries or Planned Giving:** Reach out to Nationwide Children's Hospital Foundation at (614) 722-2070 or 1-800-324-8680 for any general questions or information on making donations.
What insurance does Nationwide Children's Hospital accept?
Nationwide Children's Hospital is a "preferred provider" for various managed care plans, including Caresource Marketplace. Patients should confirm coverage and restrictions with their insurance provider before scheduling visits and procedures. It's important to ensure that your child's preferred providers are in-network, especially if choosing insurance through new health care exchanges, due to limited or no out-of-network benefits.
What awards or recognition has Nationwide Children's Hospital received?
Nationwide Children's Hospital, located in Columbus, Ohio, is renowned for its extensive clinical research, with over 1000 active projects aimed at advancing pediatric care through novel therapeutics and diagnostic tests. Since its founding in 1892, it has been at the forefront of pediatric research, including significant studies on rhinoviruses, microvolume blood testing, and pioneering the first human gene therapy trial for Duchenne muscular dystrophy. The hospital has been recognized with the James B. Recchie Design Award for its child and family-centered design and has earned accreditation from the Adult Congenital Heart Association for its exceptional service to adults with congenital heart disease.